Synlogic and Ginkgo announce clinical candidate SYNB1353 for homocystinuria; IND filing expected 2022

SYNLOGIC, INC.

SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.
First candidate from Synlogic-Ginkgo collaboration to enter IND-enabling studies.
Synlogic expects to file an IND with FDA and begin clinical development in 2022.
Preclinical data to be presented at International Congress of Inborn Errors of Metabolism 2021 (Nov 21-23).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.